Barkhof, Frederik;
Knopman, David S;
(2023)
Brain Shrinkage in Anti-β-Amyloid Alzheimer Trials: Neurodegeneration or Pseudo-atrophy?
Neurology
, 100
(20)
pp. 941-942.
10.1212/WNL.0000000000207268.
Preview |
Text
Barkhof_Editorial commentary Neurology-2022-187233 - Barkhof+Knopman.pdf Download (140kB) | Preview |
Abstract
One of the puzzling observations from anti–amyloid-β therapeutic trials for Alzheimer disease (AD) has been that treated arms fail to show preservation of brain volume. In this issue of Neurology®, Alves et al. presented a meta-analysis of anti–amyloid-β therapies and show that the agents do not slow the rate of brain volume loss. Depending on the class of drug, these new agents can even accelerate loss of whole-brain and hippocampal volume and increase ventricular volume. This association has been seen with some of the beta-secretase inhibitors and with several of the antiamyloid monoclonal antibodies.
Archive Staff Only
 |
View Item |
